Elizabeth Anne Reisinger Sprague

Title: The Innovations of Elizabeth Anne Reisinger Sprague

Introduction

Elizabeth Anne Reisinger Sprague is a notable inventor based in Concord, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting the epidermal growth factor receptor 3 (HER3). With a total of 4 patents to her name, her work has the potential to impact the treatment of various diseases.

Latest Patents

One of her latest patents involves antibodies for epidermal growth factor receptor 3 (HER3). This invention focuses on antibodies or fragments that interact with the HER family of receptors, specifically targeting a conformational epitope of the HER3 receptor. The antibodies are designed to inhibit both ligand-dependent and ligand-independent signal transduction while allowing ligand binding, such as neuregulin. This innovation holds promise for treating diseases characterized by increased levels of HER3 expression, including esophageal cancer. Additionally, these antibodies can decrease tissue weight or induce atrophy in specific tissues, such as prostate or uterine weights.

Career Highlights

Elizabeth is currently associated with Novartis AG, where she continues to advance her research and development efforts. Her work has been instrumental in the field of therapeutic antibodies, contributing to the understanding and treatment of various cancers and disorders.

Collaborations

Some of her notable coworkers include Andrew Paul Garner and Seth Alexander Ettenberg. Their collaborative efforts have further enhanced the research and development of innovative solutions in biotechnology.

Conclusion

Elizabeth Anne Reisinger Sprague's contributions to the field of biotechnology through her patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for advancements in medical treatments and therapies.